We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 3.480-0.3%May 24 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tktrimbath6/30/2021 7:49:20 PM
   of 3563
My mid-year review of GERN - crossposted, blog to go live soon

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.


GERN (market cap is $0.4549B was $0.494B)

Geron is a leading edge biotech company focused on cancer treatments, but with a telomerase technology that could have more uses than the current target of hematological (blood) disorders. They are in clinical trials (phase 3) and intend to apply for FDA approval with treatments to begin within a few years.

Geron originally had grander goals, as if curing cancer wasn't enough. They sold off their cloning business, as well as their stem cell technology (see Lineage Cell Therapeutics, LCTX, for one of my holdings that includes that spin-off). That grander company vision is from over twenty years ago. This is what is left, and what is left may be more than enough. Because their technology is so advanced they may encounter hurdles as the FDA is very conservative and cautious, even as patients could be benefiting from the treatment. If the unmet need is great enough, there may be pressure to encourage an expedited approval. That's a hard thing to predict.

One bit of encouraging news: Recently they've advanced enough that I had to check out their web site to get the dates and phases correct. That wasn't the case for many years.

"The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis." No wonder I couldn't quote that. That's biotech.

"The Company is beginning pre-commercial activities, including building the internal infrastructure to support a commercial launch. Assuming approval of the NDA, the Company forecasts the commercial launch of imetelstat in lower risk MDS in the United States to be in 2024." That's easier to understand. 2024 seemed far away years ago, but time progresses regardless. Hopefully the trials, approval, treatments, and commercial sustainability do too.

DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more now that substantial, quantitative results are to be made public. Stay tuned.

(I've also collected links to the other discussion boards and my other stocks over on my blog )
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext